Probing the interface of drugs and the human gut microbiome
Several seminars are held weekly at the Instituto Gulbenkian de Ciência, an initiative that aims to bring together all researchers around the topics under discussion.
The sessions, with internal researchers or guests, contribute to stimulate the open and extremely collaborative culture of the IGC.
You can read the abstract of this seminar to learn more about it.
Drugs both impact the human gut microbiota and their bioavailability is modified by gut microbes. Here, I will be presenting recent highlights from coordinated efforts at EMBL to systematically map this drug-microbiome interface, to understand its impact on the gut microbiota and on drug efficacy, to address whether communities have emergent behaviours against drugs, and to discover ways to mitigate the collateral damage of drugs, and especially of antibiotics, on gut microbes.